Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Other Accumulated Expenses: 2017-2024

Historic Other Accumulated Expenses for Arcus Biosciences (RCUS) over the last 8 years, with Dec 2024 value amounting to $123.0 million.

  • Arcus Biosciences' Other Accumulated Expenses rose 45.36% to $141.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.0 million, marking a year-over-year increase of 45.36%. This contributed to the annual value of $123.0 million for FY2024, which is 61.84% up from last year.
  • Per Arcus Biosciences' latest filing, its Other Accumulated Expenses stood at $123.0 million for FY2024, which was up 61.84% from $76.0 million recorded in FY2023.
  • Arcus Biosciences' Other Accumulated Expenses' 5-year high stood at $123.0 million during FY2024, with a 5-year trough of $18.3 million in FY2020.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $76.0 million (2023), whereas its average is $91.7 million.
  • Data for Arcus Biosciences' Other Accumulated Expenses shows a peak YoY soared of 300.42% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Arcus Biosciences' Other Accumulated Expenses stood at $18.3 million in 2020, then spiked by 194.97% to $54.0 million in 2021, then skyrocketed by 40.74% to $76.0 million in 2022, then remained steady at $76.0 million in 2023, then soared by 61.84% to $123.0 million in 2024.